Cargando…

Global Registries in Congenital Hyperinsulinism

Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasquini, Tai L. S., Mesfin, Mahlet, Schmitt, Jennifer, Raskin, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201947/
https://www.ncbi.nlm.nih.gov/pubmed/35721728
http://dx.doi.org/10.3389/fendo.2022.876903
_version_ 1784728426181033984
author Pasquini, Tai L. S.
Mesfin, Mahlet
Schmitt, Jennifer
Raskin, Julie
author_facet Pasquini, Tai L. S.
Mesfin, Mahlet
Schmitt, Jennifer
Raskin, Julie
author_sort Pasquini, Tai L. S.
collection PubMed
description Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatments, and identifying and managing hypoglycemia before it is prolonged and causes brain damage or death. Patient-reported data provides a basis for understanding the day-to-day experience of living with HI. Commonly identified goals of registries include performing natural history studies, establishing a network for future product and treatment studies, and supporting patients and families to offer more successful and coordinated care. Congenital Hyperinsulinism International (CHI) created the HI Global Registry (HIGR) in October 2018 as the first global patient-powered hyperinsulinism registry. The registry consists of thirteen surveys made up of questions about the patient’s experience with HI over their lifetime. An international team of HI experts, including family members of children with HI, advocates, clinicians, and researchers, developed the survey questions. HIGR is managed by CHI and advised by internationally recognized HI patient advocates and experts. This paper aims to characterize HI through the experience of individuals who live with it. This paper includes descriptive statistics on the birthing experience, hospitalizations, medication management, feeding challenges, experiences with glucose monitoring devices, and the overall disease burden to provide insights into the current data in HIGR and demonstrate the potential areas of future research. As of January 2022, 344 respondents from 37 countries consented to participate in HIGR. Parents or guardians of individuals living with HI represented 83.9% of the respondents, 15.3% were individuals living with HI. Data from HIGR has already provided insight into access challenges, patients’ and caregivers’ quality of life, and to inform clinical trial research programs. Data is also available to researchers seeking to study the pathophysiology of HI retrospectively or to design prospective trials related to improving HI patient outcomes. Understanding the natural history of the disease can also guide standards of care. The data generated through HIGR provides an opportunity to improve the lives of all those affected by HI.
format Online
Article
Text
id pubmed-9201947
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92019472022-06-17 Global Registries in Congenital Hyperinsulinism Pasquini, Tai L. S. Mesfin, Mahlet Schmitt, Jennifer Raskin, Julie Front Endocrinol (Lausanne) Endocrinology Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia in newborn babies and children. There are many areas of need for HI research. Some of the most critical needs include describing the natural history of the disease, research leading to new and better treatments, and identifying and managing hypoglycemia before it is prolonged and causes brain damage or death. Patient-reported data provides a basis for understanding the day-to-day experience of living with HI. Commonly identified goals of registries include performing natural history studies, establishing a network for future product and treatment studies, and supporting patients and families to offer more successful and coordinated care. Congenital Hyperinsulinism International (CHI) created the HI Global Registry (HIGR) in October 2018 as the first global patient-powered hyperinsulinism registry. The registry consists of thirteen surveys made up of questions about the patient’s experience with HI over their lifetime. An international team of HI experts, including family members of children with HI, advocates, clinicians, and researchers, developed the survey questions. HIGR is managed by CHI and advised by internationally recognized HI patient advocates and experts. This paper aims to characterize HI through the experience of individuals who live with it. This paper includes descriptive statistics on the birthing experience, hospitalizations, medication management, feeding challenges, experiences with glucose monitoring devices, and the overall disease burden to provide insights into the current data in HIGR and demonstrate the potential areas of future research. As of January 2022, 344 respondents from 37 countries consented to participate in HIGR. Parents or guardians of individuals living with HI represented 83.9% of the respondents, 15.3% were individuals living with HI. Data from HIGR has already provided insight into access challenges, patients’ and caregivers’ quality of life, and to inform clinical trial research programs. Data is also available to researchers seeking to study the pathophysiology of HI retrospectively or to design prospective trials related to improving HI patient outcomes. Understanding the natural history of the disease can also guide standards of care. The data generated through HIGR provides an opportunity to improve the lives of all those affected by HI. Frontiers Media S.A. 2022-06-02 /pmc/articles/PMC9201947/ /pubmed/35721728 http://dx.doi.org/10.3389/fendo.2022.876903 Text en Copyright © 2022 Pasquini, Mesfin, Schmitt and Raskin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Pasquini, Tai L. S.
Mesfin, Mahlet
Schmitt, Jennifer
Raskin, Julie
Global Registries in Congenital Hyperinsulinism
title Global Registries in Congenital Hyperinsulinism
title_full Global Registries in Congenital Hyperinsulinism
title_fullStr Global Registries in Congenital Hyperinsulinism
title_full_unstemmed Global Registries in Congenital Hyperinsulinism
title_short Global Registries in Congenital Hyperinsulinism
title_sort global registries in congenital hyperinsulinism
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201947/
https://www.ncbi.nlm.nih.gov/pubmed/35721728
http://dx.doi.org/10.3389/fendo.2022.876903
work_keys_str_mv AT pasquinitails globalregistriesincongenitalhyperinsulinism
AT mesfinmahlet globalregistriesincongenitalhyperinsulinism
AT schmittjennifer globalregistriesincongenitalhyperinsulinism
AT raskinjulie globalregistriesincongenitalhyperinsulinism